http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Suzuki, Aya,Nobusawa, Sumihito,Natsume, Atsushi,Suzuki, Hiromichi,Kim, Young-Ho,Yokoo, Hideaki,Nagaishi, Masaya,Ikota, Hayato,Nakazawa, Takuro,Wakabayashi, Toshihiko,Ohgaki, Hiroko,Nakazato, Yoichi M. Nijhoff ; Kluwer Academic Publishers 2014 Journal of neuro-oncology Vol.120 No.2
<P>Diagnosis of low-grade diffuse gliomas based on morphology is highly subjective and, therefore, is often difficult, with significant intra- and interobserver variability. Here, we investigated WHO grade II diffuse astrocytomas, oligoastrocytomas and oligodendrogliomas for immunohistochemical expression of Olig2, measuring its labeling index (LI), and evaluated the significance of Olig2 LI in the histological and molecular classifications. The means of Olig2 LI in glioma cells were 43.7 % in diffuse astrocytomas, 59.3 % in oligoastrocytomas and 76.1 % in oligodendrogliomas. There was a statistically significant difference between all pairs of histological types. The mean of Olig2 LI of gliomas with 1p/19q loss ± IDH1/2 mutation, the majority of them being oligodendrogliomas, was significantly higher than the means of those with TP53 mutation ± IDH1/2 mutation and IDH1/2 mutation only, the majority of which were diffuse astrocytomas (70.1 vs. 47.2 and 46.5 %, respectively). When categorized according to the classification of Jiao et al., Olig2 LI of I-CF gliomas (cases with IDH and one or more of CIC, FUBP1 or combined 1p/19q loss; mean 71.0 %) was significantly higher than that of I-A gliomas (cases with IDH and ATRX alterations; mean 45.3 %). These molecular classifications were reported to correlate well with clinical outcome. However, borderlines of Olig2 LI were broad and could not clearly distinguish genotypes in the molecular classifications. In conclusion, Olig2 LI cannot be taken as a complete surrogate marker for molecular genotype, but could possibly provide some ancillary information when molecular assay is not availabe.</P>
Stem cell-based therapy for inflammatory bowel disease
Hiromichi Shimizu,Kohei Suzuki,Mamoru Watanabe,Ryuichi Okamoto 대한장연구학회 2019 Intestinal Research Vol.17 No.3
Inflammatory bowel disease (IBD) is an idiopathic, multi-etiological disease characterized by inflammation and mucosal destruction of the gastrointestinal tract. Despite the remarkable advance in immunomodulating therapies, there still remains a certain population of patients who are refractory to conventional as well as biologic therapies and fail to achieve mucosal healing. To improve the prognosis of those patients, at least 2 types of stem cells have been tested for their potential therapeutic use. Transplantation of hematopoietic stem cells or mesenchymal stem cells have been tested in several clinical studies, but their beneficial effect still remains controversial. In this review, we would like to overview the recent clinical challenges of stem cell-based therapies in IBD and also introduce our new therapeutic plan of intestinal stem cell transplantation for IBD, based on our ex vivo intestinal organoid culture technique.
Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
( Hiromichi Shimizu ),( Toshimitsu Fujii ),( Shuji Hibiya ),( Maiko Motobayashi ),( Kohei Suzuki ),( Kento Takenaka ),( Eiko Saito ),( Masakazu Nagahori ),( Kazuo Ohtsuka ),( Mamoru Watanabe ) 대한장연구학회 2021 Intestinal Research Vol.19 No.1
Hiromichi Umebayashi,Tatsujiro Suzuki 한국학술연구원 2016 Korea Observer Vol.47 No.4
The 71st session of the U.N. General Assembly (UNGA) marked historic progress in the global multilateral nuclear disarmament and non-proliferation efforts. A UNGA resolution entitled “Taking forward multilateral nuclear disarmament negotiations,” which was adopted at the First Committee of the UNGA (which “deals with disarmament, global challenges and threats to peace that affect the international community and seeks out solutions to the challenges in the international security regime”) in October 2016 and is due to be adopted at the plenary session in December 2016, decides that the U.N. shall convene in 2017 a “conference to negotiate a legally binding instrument to prohibit nuclear weapons, leading towards their total elimination.”
Kokolo Ikeda,Hiromichi Suzuki,Hajime Kita,Sandor Markon 대한전자공학회 2008 ITC-CSCC :International Technical Conference on Ci Vol.2008 No.7
Multi-Car Elevator (MCE) is the novel system and attracts attention for improvement of transportation in highrise buildings, but the design of controller for MCE is very difficult engineering problem. In this paper, the works of the authors are summarized: The control of MCE is divided to four phases and the assignment of a car to a hall-call is focused. The exemplar-based policy is used for the assignment, the policy is evaluated through discrete event simulation, and the parameter is optimized by genetic algorithm. To design traffic-sensitive controller, multi-objective optimization is utilized. Finally a policy visualization method is proposed for analyzing how the policy works.
Overview of JCGGDB including New Released GlycoProtDB
Toshihide Shikanai,Hiroyuki Kaji,Yoshinori Suzuki,Noriaki Fujita,Masako Maeda,HonglingWen,Madoka Ishizaki,Hiromichi Sawaki,Hisashi Narimatsu. 한국당과학회 2012 한국당과학회 학술대회 Vol.2012 No.1
The JST/NBDC integrated database project has kicked off last year. JCGGDB was selected as a promotion program of DB integration, aiming to integrate all the glycan-related databases in Japan and build user- friendly search systems. As part of the project, the construction of ACGG-DB (an integrated database for the ACGG: Asian Communications for Glycobiology and Glycotechnology) is also planned in cooperation with Asian countries. As of now we have consolidated data from various Japanese institutes into JCGGDB and developed a cross-search function by keyword entry and integrated search functions by glycan stcurctures. These functions enabled users to easily access various glycan-related databases with a single search. Cheminformatics technologies using chemical structural formula for glycan has been also adopted to provide a search for glycan structures, glycan synthetic products by organic chemistry and recombinant enzymes, glycogene inhibitors, glycosides, and commercial glycans. This Summer, we have released AIST GlycoProtDB, which stores the data of experimentally-proven glycosylation sites on each mouse tissue. We are continuously accumulating experimental results of glycosylation sites, while collecting more information from scientific journals, toward the release of ACGG Glycoprotein Database in autumn. For the future, we will keep developing base technologies for DB integration and linking with databases related to glycoscience as well as other study areas. Some more bioinformatics tools are also being developed to support experimental study. Our aim is to create contents which could be easily and intuitively understood by every user.
Electric and Physical Chacteritics of a SiC-PiN Diode for High-Power Devices
Nam Oh Kim,Wan-Ki Min,Kyung-Min Sung,Kazuma Suzuki,Yasunori Tanaka,Hiromichi Ohashi 한국물리학회 2008 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.52 No.6
This paper is presented on a 2.5-kV silicon-carbide (SiC) PiN diode with a silicon injection enhancement gate transistor (IEGT) in an inductively loaded chopper circuit. The experimental switching characteristics of the SiC-PiN diode are presented under a DC 1200 V bias voltage and 40 A cutoff current. Experimental results show that the reverse recovery time and the IEGT turn-on loss are significantly reduced by the combination of the SiC-PiN diode and the IEGT. To reduce switching losses and investigate the limitation of the switching frequency in high power converters, we newly present the design concept of an IEGT combined with a SiC-PiN diode. The proposed design concept is evaluated based on a device simulation. The result of the device simulation yields the possible switching frequency by using the comprehensive total devices loss in the test circuit. This paper is presented on a 2.5-kV silicon-carbide (SiC) PiN diode with a silicon injection enhancement gate transistor (IEGT) in an inductively loaded chopper circuit. The experimental switching characteristics of the SiC-PiN diode are presented under a DC 1200 V bias voltage and 40 A cutoff current. Experimental results show that the reverse recovery time and the IEGT turn-on loss are significantly reduced by the combination of the SiC-PiN diode and the IEGT. To reduce switching losses and investigate the limitation of the switching frequency in high power converters, we newly present the design concept of an IEGT combined with a SiC-PiN diode. The proposed design concept is evaluated based on a device simulation. The result of the device simulation yields the possible switching frequency by using the comprehensive total devices loss in the test circuit.
홍남기,이용호,Kenichi Tsujita,Jorge A. Gonzalez,Christopher M. Kramer,Tomas Kovarnik,George N. Kouvelos,Hiromichi Suzuki,한경도,이찬주,박성하,이병완,차봉수,강은석 대한내분비학회 2018 Endocrinology and metabolism Vol.33 No.2
Background: Ezetimibe-statin combination therapy has been found to reduce low density lipoprotein cholesterol levels and the risk of major adverse cardiovascular events (MACEs) in large trials. We sought to examine the differential effect of ezetimibe on MACEs when added to statins according to the presence of diabetes. Methods: Randomized clinical trials with a sample size of at least 50 participants and at least 24 weeks of follow-up that compared ezetimibe-statin combination therapy with a statin- or placebo-controlled arm and reported at least one MACE, stratified by diabetes status, were included in the meta-analysis and meta-regression. Results: A total of seven trials with 28,191 enrolled patients (mean age, 63.6 years; 75.1% men; 7,298 with diabetes [25.9%]; mean follow-up, 5 years) were analysed. MACEs stratified by diabetes were obtained from the published data (two trials) or through direct contact (five trials). No significant heterogeneity was observed among studies (I2=14.7%, P=0.293). Ezetimibe was associated with a greater reduction of MACE risk in subjects with diabetes than in those without diabetes (pooled relative risk, 0.84 vs. 0.93; Pheterogeneity=0.012). In the meta-regression analysis, the presence of diabetes was associated with a greater reduction of MACE risk when ezetimibe was added to statins (β=0.87, P=0.038). Conclusion: Ezetimibe-statin combination therapy was associated with greater cardiovascular benefits in patients with diabetes than in those without diabetes. Our findings suggest that ezetimibe-statin combination therapy might be a useful strategy in patients with diabetes at a residual risk of MACEs.